for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zoetis Inc

ZTS.N

Latest Trade

163.49USD

Change

1.11(+0.68%)

Volume

334,299

Today's Range

162.61

 - 

164.61

52 Week Range

90.20

 - 

168.93

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
162.38
Open
163.10
Volume
334,299
3M AVG Volume
33.32
Today's High
164.61
Today's Low
162.61
52 Week High
168.93
52 Week Low
90.20
Shares Out (MIL)
475.14
Market Cap (MIL)
77,154.00
Forward P/E
--
Dividend (Yield %)
0.49

Next Event

Q3 2020 Zoetis Inc Earnings Release

Latest Developments

More

Zoetis Q2 Adjusted Earnings Per Share $0.89

Zoetis Says Pricing Of $1.25 Billion Of Senior Notes

Zoetis Reports Q1 Adjusted Earnings Per Share $0.95

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zoetis Inc

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Industry

Biotechnology & Drugs

Contact Info

10 Sylvan Way

PARSIPPANY, NJ

07054-3825

United States

+1.973.8227000

https://www.zoetis.com/

Executive Leadership

Michael B. McCallister

Non-Executive Independent Chairman of the Board

Kristin C. Peck

Chief Executive Officer, Director

Glenn C. David

Chief Financial Officer, Executive Vice President

Roxanne Lagano

Chief Human Resource Officer, Executive Vice President and Global Operations

Heidi C. Chen

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

2.05 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

5.3K

2018

5.8K

2019

6.3K

2020(E)

6.4K
EPS (USD)

2017

2.400

2018

3.130

2019

3.640

2020(E)

3.633
Price To Earnings (TTM)
48.03
Price To Sales (TTM)
12.17
Price To Book (MRQ)
25.87
Price To Cash Flow (TTM)
37.58
Total Debt To Equity (MRQ)
258.05
LT Debt To Equity (MRQ)
241.25
Return on Investment (TTM)
15.27
Return on Equity (TTM)
13.44

Latest News

Latest News

BRIEF-Trianni And Zoetis Announce Agreement To Develop A Transgenic Antibody Discovery Platform For Use In Animal Health

* TRIANNI AND ZOETIS ANNOUNCE AGREEMENT TO DEVELOP A TRANSGENIC ANTIBODY DISCOVERY PLATFORM FOR USE IN ANIMAL HEALTH

BRIEF-VIB Vermoegen Q1 Adjusted EBT Up At EUR 14.6 Mln

* CONTINUES ITS SUCCESSFUL GROWTH TRAJECTORY IN THE FIRST QUARTER OF 2020

BRIEF-Zoetis Says Pricing Of $1.25 Billion Of Senior Notes

* AGREED TO SELL $1.25 BILLION OF SENIOR NOTES, CONSISTING OF $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 2.000% SENIOR NOTES DUE 2030

BRIEF-Zoetis Files Prospectus Supplement Related To A Potential Two-Part Senior Notes Offering - SEC Filing

* ZOETIS INC FILES PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART SENIOR NOTES OFFERING - SEC FILING

BRIEF-Zoetis Reports Q1 Adjusted Earnings Per Share $0.95

* Q1 REVENUE $1.5 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.5 BILLION

Animal health leader Zoetis steps into pet insurance

Zoetis Inc <ZTS.N>, the world's largest animal health company, unveiled a new insurance unit in a bid to take advantage of rising pet ownership as Americans adopt furry companions to help relieve the loneliness of coronavirus lockdowns.

BRIEF-Zoetis Recommends Stockholders Reject Mini-Tender Offer By TRC Capital Investment Corp

* ZOETIS RECOMMENDS STOCKHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL INVESTMENT CORPORATION Source text for Eikon: Further company coverage:

BRIEF-Zoetis Says CEO Juan Ramón Alaix's FY 2019 Total Compensation Was $21.1 Mln Vs $11.7 Mln In 2018

* ZOETIS INC SAYS CEO JUAN RAMÓN ALAIX'S FY 2019 TOTAL COMPENSATION WAS $21.1 MILLION VERSUS $11.7 MILLION IN 2018 - SEC FILING

BRIEF-Zoetis Receives FDA Approval For Simparica Trio

* ZOETIS RECEIVES FDA APPROVAL FOR SIMPARICA TRIO™, A NEW COMBINATION PARASITE PREVENTATIVE FOR DOGS

BRIEF-Zoetis Reports Q4 EPS Of $0.80

* Q4 REVENUE $1.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.64 BILLION

BRIEF-Zoetis Inc Acquires Ethos Diagnostic Science

* ZOETIS ACQUIRES ETHOS DIAGNOSTIC SCIENCE, A VETERINARY REFERENCE LAB BUSINESS, TO FURTHER EXPAND ITS COMPREHENSIVE DIAGNOSTICS CAPABILITIES

Factbox: Animal health sector aims to emulate Zoetis biotech leap

A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis <ZTS.N> has roused rivals to action in a hunt for biotechnology medicines to treat pets.

Biotech is going to the dogs - and big profits await

For Jessica Lescault there is no question that her 6-year old English bulldog "Moose" deserves cutting-edge biotechnology cancer treatment as much as any human patient.

Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion

Top animal health company Zoetis Inc <ZTS.N> will buy Abaxis Inc <ABAX.O> for $1.9 billion, looking to capture a bigger slice of the fast-growing market for diagnostics services that cater to household pets and farm animals.

BRIEF-Abaxis Inc - Upon Termination Of Merger By Co Or Zoetis Upon Specified Conditions, Termination Fee Of $70 Mln May Be Payable By Co To Zoetis

* ABAXIS INC - UPON TERMINATION OF MERGER BY CO OR ZOETIS UPON SPECIFIED CONDITIONS, TERMINATION FEE OF $70 MILLION MAY BE PAYABLE BY CO TO ZOETIS

BRIEF-Zoetis Says Upon Deal Termination By Abaxis Or Co, Termination Fee Of $70 Mln May Be Payable By Abaxis

* ZOETIS SAYS UPON DEAL TERMINATION BY ABAXIS OR CO, TERMINATION FEE OF $70 MILLION MAY BE PAYABLE BY ABAXIS - SEC FILING Source text: (https://bit.ly/2KprpqL) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Zoetis To Acquire Abaxis for about $2 Bln In Aggregate

* ZOETIS TO ACQUIRE ABAXIS, A LEADING GLOBAL PROVIDER OF VETERINARY POINT-OF-CARE DIAGNOSTIC INSTRUMENTS

Zoetis to buy Abaxis for $1.9 bln in cash

Animal health company Zoetis Inc said on Wednesday it would buy Abaxis Inc, a maker of veterinary diagnostic instruments, for about $1.9 billion in cash.

BRIEF-Anatara Lifesciences Announces Exclusive Global License Agreement With Zoetis

* ANNOUNCES EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH ZOETIS Source text for Eikon: Further company coverage:

BRIEF-Zoetis Announces Q1 Earnings Per Share $0.72

* Q1 EARNINGS PER SHARE VIEW $0.69 -- THOMSON REUTERS I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up